Published Online
on February 1, 2007

A more recent version of this article appeared on March 1, 2007

This Article Full Text (PDF) All Versions of this Article: 38/3/1091    most recent 01.STR.0000258355.23810.c6v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Banks, J. L. Articles by Marotta, C. A. Search for Related Content PubMed PubMed Citation Articles by Banks, J. L. Articles by Marotta, C. A. Pubmed/NCBI databases Medline Plus Health Information Stroke Related Collections Health policy and outcome research Cerebrovascular disease/stroke Neuroprotectors Thrombolysis

Submitted on August 29, 2006
Revised on October 5, 2006
Accepted on October 6, 2006

Outcomes Validity and Reliability of the Modified Rankin Scale: Implications for Stroke Clinical Trials. A Literature Review and Synthesis

Jamie L. Banks MSc, PhD and Charles A. Marotta MD, PhD^*

From the Health Economics Research and Quality of Life Evaluation Services (J.L.B.), Abt Associates, Inc, Lexington, Mass; and Health Economics and Outcomes Research (C.A.M.), Division of Medical Sciences, AstraZeneca Pharmaceuticals LP, Wilmington, Del.

^* To whom correspondence should be addressed. E-mail: charles.marotta{at}astrazeneca.com.

Background and Purpose--The modified Rankin scale (mRS), a clinician-reported measure of global disability, is widely applied for evaluating stroke patient outcomes and as an end point in randomized clinical trials. Extensive evidence on the validity of the mRS exists across a large but fragmented literature. As new treatments for acute ischemic stroke are submitted for agency approval, an appreciation of the mRS’s attributes, specifically its relationship to other stroke evaluation scales, would be valuable for decision-makers to properly assess the impact of a new drug on treatment paradigms. The purpose of this report is to assemble and systematically assess the properties of the mRS to provide decision-makers with pertinent evaluative information.

Methods--A Medline search was conducted to identify reports in the peer-reviewed medical literature (1957-2006) that provide information on the structure, validation, scoring, and psychometric properties of the mRS and its use in clinical trials. The selection of articles was based on defined criteria that included relevance, study design and use of appropriate statistical methods.

Results--Of 224 articles identified by the literature search, 50 were selected for detailed assessment. Inter-rater reliability with the mRS is moderate and improves with structured interviews ( 0.56 versus 0.78); strong test-re-test reliability (=0.81 to 0.95) has been reported. Numerous studies demonstrate the construct validity of the mRS by its relationships to physiological indicators such as stroke type, lesion size, perfusion and neurological impairment. Convergent validity between the mRS and other disability scales is well documented. Patient comorbidities and socioeconomic factors should be considered in properly applying and interpreting the mRS. Recent analyses suggest that randomized clinical trials of acute stroke treatments may require a smaller sample size if the mRS is used as a primary end point rather than the Barthel Index.

Conclusions--Multiple types of evidence attest to the validity and reliability of the mRS. The reported data support the view that the mRS is a valuable instrument for assessing the impact of new stroke treatments.

Key words: cerebrovascular accident • disability evaluation • randomized controlled trials • rankin scale • reproducibility of results

This article has been cited by other articles:

				A. M. Naidech, B. Jovanovic, S. Liebling, R. K. Garg, S. L. Bassin, B. R. Bendok, R. A. Bernstein, M. J. Alberts, and H. H. Batjer Reduced Platelet Activity Is Associated With Early Clot Growth and Worse 3-Month Outcome After Intracerebral Hemorrhage Stroke, July 1, 2009; 40(7): 2398 - 2401. [Abstract] [Full Text] [PDF]

				T. J. Quinn, J. Dawson, M. R. Walters, and K. R. Lees Exploring the Reliability of the Modified Rankin Scale Stroke, March 1, 2009; 40(3): 762 - 766. [Abstract] [Full Text] [PDF]

				Cumberland Consensus Working Group, B. Cheeran, L. Cohen, B. Dobkin, G. Ford, R. Greenwood, D. Howard, M. Husain, M. Macleod, R. Nudo, et al. The Future of Restorative Neurosciences in Stroke: Driving the Translational Research Pipeline From Basic Science to Rehabilitation of People After Stroke Neurorehabil Neural Repair, February 1, 2009; 23(2): 97 - 107. [Abstract] [PDF]

				R. Al-Shahi Salman, M. J. Berg, L. Morrison, I. A. Awad, and on behalf of the Angioma Alliance Scientific Advis Hemorrhage From Cavernous Malformations of the Brain: Definition and Reporting Standards Stroke, December 1, 2008; 39(12): 3222 - 3230. [Abstract] [Full Text] [PDF]

				T. J. Quinn, J. Dawson, M. R. Walters, and K. R. Lees Variability in Modified Rankin Scoring Across a Large Cohort of International Observers Stroke, November 1, 2008; 39(11): 2975 - 2979. [Abstract] [Full Text] [PDF]

				G. Green and J. Todd 'Restricting choices and limiting independence': social and economic impact of multiple sclerosis upon households by level of disability Chronic Illness, September 1, 2008; 4(3): 160 - 172. [Abstract] [PDF]

				T. J. Quinn, J. Dawson, M. R. Walters, and K. R. Lees Reliability of the Modified Rankin Scale Stroke, November 1, 2007; 38(11): e144 - e144. [Full Text] [PDF]

				J. L. Banks and C. A. Marotta Response to Letter by Quinn et al Stroke, November 1, 2007; 38(11): e145 - e145. [Full Text] [PDF]